Surrogate study endpoints in the era of cancer immunotherapy

  • Hamada T
  • Kosumi K
  • Nakai Y
  • et al.
N/ACitations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

The choice of a primary endpoint is a matter of ongoing debate in the design of clinical oncology trials testing new treatment regimens. Overall survival (OS) time of patients serves as a gold-standard endpoint in phase III clinical trials testing first-line chemotherapy for cancers, because this outcome variable ultimately represents survival benefits from chemotherapy regimens and has minimal measurement errors.

Cite

CITATION STYLE

APA

Hamada, T., Kosumi, K., Nakai, Y., & Koike, K. (2018). Surrogate study endpoints in the era of cancer immunotherapy. Annals of Translational Medicine, 6(S1), S27–S27. https://doi.org/10.21037/atm.2018.09.31

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free